Agios Pharma Statistics
Want to see AGIO full AI Analyst Report?
Agios Pharma (AGIO) Stock Statistics & Valuation Metrics
Total Valuation
Agios Pharma has a market cap or net worth of $1.90B. The enterprise value is $1.38B.
- Market Cap
- $1.90B
- Enterprise Value
- $1.38B
Share Statistics
Agios Pharma has 59,809,650 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 59,809,650
- Owned by Insiders
- 1.11%
- Owned by Institutions
- 58.17%
Financial Efficiency
Agios Pharma’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.18%.
- Return on Equity (ROE)
- -0.35
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -38.18%
- Return on Capital Employed (ROCE)
- -0.39
- Revenue Per Employee
- 100.05K
- Profits Per Employee
- -764.41K
- Employee Count
- 540
- Asset Turnover
- 0.04
- Inventory Turnover
- 0.35
Valuation Ratios
The current PE Ratio of Agios Pharma is -5.00. Agios Pharma’s PEG ratio is -0.58.
- PE Ratio
- -5.00
- PS Ratio
- 13.41
- PB Ratio
- 1.93
- Price to FCF
- -5.62
- Price to Operating Cash Flow
- -5.69
- PEG Ratio
- -0.58
Income Statement
In the last 12 months, Agios Pharma had revenue of 54.03M and earned -412.78M in profits. Earnings per share was -7.12.
- Revenue
- 54.03M
- Gross Profit
- 42.51M
- Operating Income
- -472.13M
- Pretax Income
- -413.80M
- Net Income
- -412.78M
- EBITDA
- -408.62M
- Earnings Per Share (EPS)
- -7.12
Cash Flow
In the last 12 months, operating cash flow was -331.68M and capital expenditures -4.28M, giving a free cash flow of -335.97M billion.
- Operating Cash Flow
- -331.68M
- Free Cash Flow
- -335.97M
- Free Cash Flow per Share
- -5.63
Dividends & Yields
Agios Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -17.75%
- Earnings Yield
- -19.73%
Stock Price Statistics
- Beta
- 1.64
- 52-Week Price Change
- -25.74%
- 50-Day Moving Average
- 33.14
- 200-Day Moving Average
- 31.92
- Relative Strength Index (RSI)
- 46.77
- Average Volume (3m)
- 1.07M
Important Dates
Agios Pharma upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Agios Pharma as a current ratio of 11.46, with Debt / Equity ratio of 3.37%
- Current Ratio
- 11.46
- Quick Ratio
- 11.06
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.12
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Agios Pharma has paid -1.02M in taxes.
- Income Tax
- -1.02M
- Effective Tax Rate
- 0.00
Enterprise Valuation
Agios Pharma EV to EBITDA ratio is -4.73, with an EV/FCF ratio of -5.33.
- EV to Sales
- 12.72
- EV to EBITDA
- -4.73
- EV to Free Cash Flow
- -5.33
- EV to Operating Cash Flow
- -5.40
Balance Sheet
Agios Pharma has $630.01M in cash and marketable securities with $26.53M in debt, giving a net cash position of $603.48M billion.
- Cash & Marketable Securities
- $630.01M
- Total Debt
- $26.53M
- Net Cash
- $603.48M
- Net Cash Per Share
- $10.09
- Tangible Book Value Per Share
- $16.40
Margins
Gross margin is 91.94%, with operating margin of -297.72%, and net profit margin of -264.76%.
- Gross Margin
- 91.94%
- Operating Margin
- -297.72%
- Pretax Margin
- -265.48%
- Net Profit Margin
- -264.76%
- EBITDA Margin
- -268.62%
- EBIT Margin
- -272.48%
Analyst Forecast
The average price target for Agios Pharma is $45.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $45.80
- Price Target Upside
- 44.98% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 214.44%
- EPS Growth Forecast
- 9.13%
Scores
- Smart Score
- 10
- AI Score
- 55
